Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2014-11-06
2019-04-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. A significant reduction of pain and swelling of the affected DVT leg
2. An increase in the quality of life (QOL) for individuals with DVT of the leg
3. Improved signs and symptoms of the post thrombotic syndrome of the affected DVT leg
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Single Session Percutaneous Mechanical Thrombectomy for the Treatment of Ilio-femoral Deep Vein Thrombosis: A Preliminary Evaluation
NCT02066597
Catheter-directed Thrombolysis Compared to Anticoagulation Alone for Acute Primary Iliofemoral Deep Venous Thrombosis
NCT04411316
Deep Venous Thrombus Characteristics and Venous Dynamics With Subsequent Thrombus Resolution and Post-thrombotic Syndrome
NCT04597138
Venous Thrombectomy/Thrombolysis Outcome Registry
NCT02113475
Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)
NCT03465735
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Assessment Only
Subjects will have an osteopathic assessment to determine areas of tension in specific areas of the body. These areas include: the thoracic diaphragm, the heart and pericardium, the iliac fascia, the femoral sheath, the sartorius muscle, the pelvic diaphragm and the interosseous membrane (IM) of the lower extremity
No interventions assigned to this group
Assessment and Treatment
Subjects will have an osteopathic assessment to determine areas of tension in specific areas of the body. These areas of tension will receive osteopathic treatment, using myofascial release techniques. These areas include: the thoracic diaphragm, the heart and pericardium, the iliac fascia, the femoral sheath, the sartorius muscle, the pelvic diaphragm and the interosseous membrane (IM) of the lower extremity
Osteopathic Treatment
The osteopathic treatment will be a gentle hands treatment using myofascial release techniques.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Osteopathic Treatment
The osteopathic treatment will be a gentle hands treatment using myofascial release techniques.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* first episode of symptomatic objectively confirmed proximal leg DVT without pulmonary embolism
* 1 month of appropriate anticoagulation treatment
* therapeutic level of anticoagulation (ie: Warfarin, INR- 2.0-3.0)
Exclusion Criteria
* history of previously confirmed proximal or distal leg DVT
* medically unstable individuals requiring hospitalization
* history of peripheral vascular disease (PVD)
* injury of affected leg (trauma within the last 6 months or leg currently casted)
* history of previous stroke
* uncontrolled hypertension
* renal failure requiring hemodialysis or peritoneal dialysis
* diagnosis of cancer in the last five years or currently receiving treatment for cancer
* open heart or vascular surgery in the last year
* any neurological condition (ie: MS, ALS, Parkinsons, etc)
* currently pregnant
* geographic inaccessibility
* unable to provide informed consent
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nova Scotia Health Authority
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Darlene D MacLeod, BscN DOMP
Role: PRINCIPAL_INVESTIGATOR
Nova Scotia Health Authority
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
QEll Health Sciences Centre
Halifax, Nova Scotia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REB ROMEO # 1017573
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.